Results 181 to 190 of about 41,743 (197)

Tofacitinib

Reactions Weekly, 2016
openaire   +1 more source

Tofacitinib in juvenile idiopathic arthritis

Lancet, The, 2021
Sarah L N Clarke, Athimalaipet V Ramanan
exaly  

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Lancet, The, 2017
Roy M Fleischmann, Robert J Moots, Liza Takiya   +2 more
exaly  

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

Lancet, The, 2015
Hervé Bachelez, Peter C M Van De Kerkhof, Alexey Kubanov   +2 more
exaly  

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

New England Journal of Medicine, 2017
Philip J Mease, Oliver Fitzgerald Mb Bch Bao, Mrcpi, Mrcp, Frcpi,, Frcp, Joseph F Merola   +2 more
exaly  

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

New England Journal of Medicine, 2017
Dafna D Gladman, William F C Rigby, Valderilio Feijó Azevedo   +2 more
exaly  

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Lancet, The, 2013
Gerd R Burmester, Ricardo Blanco, Gene Wallenstein   +2 more
exaly  

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

New England Journal of Medicine, 2012
Subrata Ghosh, Julian Panes
exaly  

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

New England Journal of Medicine, 2012
Roy M Fleischmann, Joel M Kremer, Hendrik Schulze-Koops   +2 more
exaly  

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy

New England Journal of Medicine, 2020
Khashayar Esfahani
exaly